On Tuesday, Amplify entered the weight loss ETF space with the launch of the Amplify Weight Loss Drug & Treatment ETF (THNR). THNR operates with a net expense ratio of 0.59%. Additionally, the fund aims to provide investors with results similar to the performance of the VettaFi Weight Loss Drug & Treatment Index (THINR). THINR [...] The post Amplify Debuts New Weight Loss Drug ETF appeared first on ETF Trends .